Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (241-250 of 336) with videos related to

Pageof 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patientsLynn G Dressler, Donald A Berry, Gloria Broadwater, et al.
The New England Journal of Medicine|October 12, 2007
HER2 and response to paclitaxel in node-positive breast cancerDaniel F Hayes, Ann D Thor, Lynn G Dressler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897Christine B Ambrosone, William E Barlow, Wanda Reynolds, et al.
Biopreservation and Biobanking|August 10, 2011
Biospecimen Reporting for Improved Study QualityHelen M Moore, Andrea Kelly, Scott D Jewell, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyCesar A Santa-Maria, Amanda Blackford, Anne T Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerAntonio C Wolff, Ann A Lazar, Igor Bondarenko, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Cancer Research Communications|June 28, 2023
Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response AssessmentAki Morikawa, Jinju Li, Peter Ulintz, et al.
Pageof 34

Showing results (241-250 of 336) with videos related to

Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patientsLynn G Dressler, Donald A Berry, Gloria Broadwater, et al.
The New England Journal of Medicine|October 12, 2007
HER2 and response to paclitaxel in node-positive breast cancerDaniel F Hayes, Ann D Thor, Lynn G Dressler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897Christine B Ambrosone, William E Barlow, Wanda Reynolds, et al.
Biopreservation and Biobanking|August 10, 2011
Biospecimen Reporting for Improved Study QualityHelen M Moore, Andrea Kelly, Scott D Jewell, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyCesar A Santa-Maria, Amanda Blackford, Anne T Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerAntonio C Wolff, Ann A Lazar, Igor Bondarenko, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Cancer Research Communications|June 28, 2023
Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response AssessmentAki Morikawa, Jinju Li, Peter Ulintz, et al.
Pageof 34